Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.49 |
| ▸ | BRD2 | P25440 | 5/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835884 | 1.00 | BRD4 (0.53) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL5835887 | 1.00 | BRD4 (0.53) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL18407442 | 0.85 | NOTUM (0.51) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL18407443 | 0.78 | NOTUM (0.57) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL225464 | 0.78 | PTGDR2 (0.54) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL222033 | 0.78 | PTGDR2 (0.54) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL225463 | 0.78 | PTGDR2 (0.54) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL223899 | 0.77 | NOTUM (0.55) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL253608 | 0.77 | NOTUM (0.55) | BRD4PTGDR2BRD2BRD3NOTUM | |
| SCHEMBL10270644 | 0.77 | NOTUM (0.55) | BRD4PTGDR2BRD2BRD3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030246-B2 | Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20040132724-A1 | Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132724-A1 | Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof | STAT6, HRH4, HRH1 | BRD4 39/4885PTGDR2 1376/4885BRD2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.